Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Gastrointestinal and genitourinary toxicity profiles of metformin versus placebo in men with prostate cancer receiving prostate radiotherapy: interim toxicity results of a double-blinded, multicenter, phase II randomized controlled trial

Abstract Androgen deprivation therapy (ADT) used for prostate cancer (PCa) management is associated with metabolic and anthropometric toxicity. Metformin given concurrent to ADT is hypothesized to counteract these changes. This planned interim analysis reports the gastrointestinal and genitourinary...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Julian O. Kim, Megan O. McDonald, Aldrich Ong, Rashmi Koul, Arbind Dubey, William Hunter, Shahida Ahmed, Harvey Quon, Don Yee, Matthew Parliament, Gokulan Sivananthan, Brita Danielson, Lindsay Rowe, Sunita Ghosh, Nawaid Usmani
Formato: article
Lenguaje:EN
Publicado: BMC 2021
Materias:
Metformin
Prostate cancer
Gastrointestinal toxicity
Genitourinary toxicity
Medical physics. Medical radiology. Nuclear medicine
R895-920
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/8e04f6c57db3446ca965c661d060cba7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/8e04f6c57db3446ca965c661d060cba7

Ejemplares similares